Modular Regulatory Strategy Creates Defined Milestone Cadence, Enables Earlier FDA Engagement, and Supports Targeted Final Clinical Module Submission Planned for Q2 2027
White Bear Lake, Minnesota--(Newsfile Corp. - June 30, 2026) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical" or the "Company"), a hearing health company pioneering fully implanted hearing solutions, today announced the submission of the first module of its Modular Premarket Approval ("PMA") application to the U.S. Food and Drug Administration ("FDA") for its FDA Breakthrough Device-designated product.
The submission marks the first regulatory milestone in the Company's planned modular PMA strategy. Unlike a traditional PMA, which is submitted as a single comprehensive application, the modular PMA pathway allows the Company to submit completed sections to the FDA for review as they become available, rather than waiting to compile and submit the entire submission at once. Envoy Medical expects to submit a total of four modules, with the final module containing final clinical trial data targeted for submission in the second quarter of 2027.
By utilizing the modular PMA pathway, the Company expects to engage with the FDA throughout the review process, allowing for earlier regulatory feedback while establishing a series of defined development milestones. Management believes this approach provides investors with greater visibility into the Company's progress and may reduce execution risk by identifying potential issues earlier in the review process.
"We believe the modular PMA approach is the right strategy for advancing our breakthrough-designated device through the FDA review process," said Brent Lucas, Chief Executive Officer of Envoy Medical." This submission represents the first of several milestones that we expect to achieve over the coming quarters. Rather than concentrating regulatory risk into a single binary event at the end of a multi-year process, this approach gives us a roadmap with meaningful accomplishments along the way. Each submitted module enables ongoing engagement with the FDA and creates a clearer framework for measuring our execution. We remain focused on advancing what we believe is a differentiated hearing solution for a large population of people interested in Invisible Hearing® technology."
Key advantages of the modular PMA approach for Envoy Medical include:
Earlier FDA Engagement: The FDA can begin reviewing submitted modules, such as nonclinical data and manufacturing information, while the clinical trial is ongoing, allowing the review process to progress in parallel with remaining data collection.
Iterative Feedback and Risk Reduction: Receiving FDA input on individual modules allows the Company to address any questions or concerns proactively, reducing the chance of unanticipated issues or delays upon final submission. The Company believes this proactive approach reflects prudent use of capital and helps to reduce the risk profile of the overall regulatory process.
A Structured Investor Roadmap: With four planned modules, Envoy Medical expects to have multiple opportunities to report meaningful progress to investors over the next year, providing investor visibility into the Company's advancement toward a potential approval decision.
Aligned with Breakthrough Device Designation: As an FDA-designated Breakthrough Device, Envoy Medical's product is eligible for more intensive FDA interaction and guidance throughout the review process. The modular PMA structure, which requires FDA agreement and alignment on the submission framework in advance, is a natural fit for this level of ongoing collaboration with the FDA.